Russell P. Rosenberg, PhD, is currently the chief science officer and CEO of NeuroTrials Research, Inc. and the director of the Atlanta School of Sleep Medicine and Technology in Atlanta, GA. Dr. Rosenberg was the Principle Investigator of the two pivotal Phase III SUNRISE 2 and 1 trials, evaluating Dayvigo (lemborexant) for adults with sleep onset and/or sleep maintenance (insomnia). The U.S. FDA approved Dayvigo in December of 2019 based on the results of the two trials.
Dr. Rosenberg received his Ph.D. in Clinical Research Psychology from Ohio State University and completed a residency in Behavioral Medicine and Sleep Disorders at Rush Presbyterian-St. Luke’s Medical Center. His areas of expertise include insomnia and disorders of excessive daytime sleepiness. With over 25 years of experience in clinical sleep medicine and research, Dr. Rosenberg is a Board-Certified Sleep Specialist and Fellow of the American Academy of Sleep Medicine. He served as the Chairman of National Sleep Foundation from July 2011 to August 2013. Dr. Rosenberg is also the founder & director of the Atlanta School of Sleep Medicine, where he lectures and teaches internationally on a range of sleep medicine topics. His areas of expertise include insomnia and disorders of excessive daytime sleepiness.